Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Arrowhead Pharmaceuticals, Inc.

< Previous 1 2 3 4 Next >
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals to Participate in Piper Sandler 35th Annual Healthcare Conference
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Year End Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals to Participate in Jefferies London Healthcare Conference
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals to Present New Phase 2 Clinical Data on Cardiometabolic Pipeline at AHA 2023
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals to Participate in Upcoming October 2023 Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Presents Data on Pulmonary Pipeline at ERS 2023
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals to Participate in Upcoming September 2023 Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Reports Fiscal 2023 Third Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1/2 Study of ARO-DUX4 for Facioscapulohumeral Muscular Dystrophy
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1 Study of ARO-SOD1
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Presents Updated Data from Phase 2 SEQUOIA Study of Investigational RNAi Therapy Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Liver Disease
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals to Participate in Upcoming June 2023 Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Hosts R&D Day Highlighting Its Pipeline of RNAi Therapeutics
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals to Participate in Upcoming Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Reports Fiscal 2023 Second Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals’ Proprietary Pulmonary TRiM™ Platform Achieves High Levels of Target Gene Knockdown and Long Duration of Effect
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Second Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals to Host R&D Day on Pipeline of RNAi Therapeutics
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
First Patient Treated in Alpha-1 Antitrypsin Deficiency Liver Disease Phase 3 Study Triggering $40 Million Milestone Payment from Takeda to Arrowhead
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Receives FDA Fast Track Designation for ARO-APOC3
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals to Present at 43rd Annual Cowen Health Care Conference
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Announces Interim Results from Ongoing Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Reports Fiscal 2023 First Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals to Webcast Fiscal 2023 First Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals to Present Topline Data from the Phase 2 SEQUOIA Study Evaluating Fazirsiran and Describe Design for Planned Phase 3 Study
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
Arrowhead Pharmaceuticals Announces $25 Million Milestone Payment from Amgen
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Tickers ARWR
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.